Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results

Trefzer, Uwe; Herberth, Gunda; Wohlan, Karolina; Milling, Annett; Thiemann, Max; Sharav, Tumenjargal; Sparbier, Katrin; Sterry, Wolfram; Walden, Peter

doi:10.1016/j.vaccine.2005.01.081

Cited by 65 publications

(45 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[16][17][18][19][20] Phase I/II clinical trials of DC/tumor cell fusion vaccines have been reported in patients with a range of tumors, including melanoma, renal and breast cancers, and multiple myeloma. [21][22][23][24][25][26][27][28][29] As is often the case, the results in clinical trials of DC/tumor fusion vaccines have been much less dramatic than in immunity (derived from the parent APC) (Fig. 1).…”

Section: The Concept Of Apc/tumor Fusion Cell Vaccinesmentioning

confidence: 97%

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

Browning

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Section: The Concept Of Apc/tumor Fusion Cell Vaccinesmentioning

confidence: 97%

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

Browning

2013

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…For example, in a study of DC/tumour cell hybrid vaccination in patients with stage III/IV melanoma, Trefzer et al reported 1 complete clinical remission, 1 partial response and 6 cases of disease stabilization in 17 patients studied, with 11 of 14 patients analysed demonstrating T-cell responses to tumour-associated T-cell epitopes [44,45]. Similarly, in a study of 21 renal cell cancer patients vaccinated with autologous tumour/allogeneic dendritic cell fusions, 2 showed partial clinical responses and 8 showed disease stabilization [46].…”

Section: Dendritic Cell/tumour Fusion Hybrids and Their Utility In Camentioning

confidence: 99%

Antigen-Presenting Cell/Tumour Cell Hybrid Vaccines in Cancer Immunotherapy

Mohamed¹,

Khalaf²,

Browning³

2017

Immunotherapy - Myths, Reality, Ideas, Future

View full text Add to dashboard Cite

show abstract

“…(Boczkowski et al, 1996;Nestle et al, 1998;Rosenberg et al, 1998;Svane et al, 2003;Ridgway, 2003;Schadendorf et al, 2006). As an alternative, DCs pulsed or loaded with tumors or tumor lysates from the same patient have been used to induce stronger and longer immune responses against tumors (O´Rourke et al, 2003;Nagayama et al, 2003;Hersey et al, 2004;Trefzer et al, 2005). This strategy has the advantage of providing tumor antigens capable of being presented in MHC class I and class II molecules by DCs, thus reducing the tumor escape.…”

Section: Dendritic Cells As Cancer Vaccinesmentioning

confidence: 99%

TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer

et al. 2013

View full text Add to dashboard Cite

Here we summarize 10 years of eff ort in the development of a biomedical innovation with global projections. This innovation consists of a novel method for the production of therapeutic dendritic-like cells called Tumor Antigen Presenting Cells (TAPCells ® ). TAPCells-based immunotherapy was tested in more than 120 stage III and IV melanoma patients and 20 castration-resistant prostate cancer patients in a series of phase I and I/II clinical trials. TAPCells vaccines induced T cell-mediated memory immune responses that correlated with increased survival in melanoma patients and prolonged prostate-specifi c antigen doubling time in prostate cancer patients. Importantly, more than 60% of tested patients showed a Delayed Type Hypersensitivity (DTH) reaction against the lysates, indicating the development of anti-tumor immunological memory that correlates with clinical benefi ts. The in vitro analysis of the lysate mix showed that it contains damage-associated molecular patterns such as HMBG-1 protein which are capable to improve, through Toll-like receptor-4, maturation and antigen cross-presentation of the dendritic cells (DC). In fact, a Toll-like receptor-4 polymorphism correlates with patient clinical outcomes. Moreover, Concholepas concholepas hemocyanin (CCH) used as adjuvant proved to be safe and capable of enhancing the immunological response. Furthermore, we observed that DC vaccination resulted in a three-fold increase of T helper-1 lymphocytes releasing IFN-γ and a two-fold increase of T helper-17 lymphocytes capable of producing IL-17 in DTH+ with respect to DTH-patients. Important steps have been accomplished for TAPCells technology transfer, including patenting, packaging and technology assessment. Altogether, our results indicate that TAPCells vaccines constitute an exceptional Chilean national innovation of international value.

show abstract

Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results

Cited by 65 publications

References 37 publications

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

Antigen presenting cell/ tumor cell fusion vaccines for cancer immunotherapy

Antigen-Presenting Cell/Tumour Cell Hybrid Vaccines in Cancer Immunotherapy

TAPCells, the Chilean dendritic cell vaccine against melanoma and prostate cancer

Contact Info

Product

Resources

About